Are the Shorts Right About Obesity Drugs?
Dec 18th 2012 6:30PM
Updated Dec 18th 2012 6:46PM
While Arena Pharmaceuticals and VIVUS , makers of the obesity drugs Belviq and Qsymia, respectively, both garner a lot of attention on Fool.com, they also have attracted the attention of the short sellers. In this video, Motley Fool health-care analyst David Williamson talks about the "buy the run-up, short the launch" trend, and whether the short-sellers are right not to believe in these stocks.
The potential market for obesity drugs is massive, but so are the risks. If you're looking for more information on the top two obesity drug players, grab copies of our premium research reports on Arena Pharmaceuticals and VIVUS today. In the reports, our senior biotech analyst, Brian Orelli, Ph.D., breaks down each company's strengths and weaknesses and explains the critical issues you need to know about. News in this space moves fast, so both reports come with a full year of updates. Click now for exclusive information on Arena and VIVUS.
The article Are the Shorts Right About Obesity Drugs? originally appeared on Fool.com.David Williamson owns shares of Amarin. Follow him on Twitter, @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.